vs
Side-by-side financial comparison of Sunshine Biopharma Inc. (SBFM) and SES AI Corp (SES). Click either name above to swap in a different company.
Sunshine Biopharma Inc. is the larger business by last-quarter revenue ($8.6M vs $4.6M, roughly 1.9× SES AI Corp). Sunshine Biopharma Inc. runs the higher net margin — -25.0% vs -373.5%, a 348.5% gap on every dollar of revenue. Sunshine Biopharma Inc. produced more free cash flow last quarter ($-1.6M vs $-11.1M).
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.
SBFM vs SES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $4.6M |
| Net Profit | $-2.1M | $-17.0M |
| Gross Margin | 35.3% | 11.3% |
| Operating Margin | -20.9% | -387.7% |
| Net Margin | -25.0% | -373.5% |
| Revenue YoY | -10.6% | — |
| Net Profit YoY | 0.8% | 50.7% |
| EPS (diluted) | — | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $4.6M | ||
| Q3 25 | $9.4M | $7.1M | ||
| Q2 25 | $9.4M | $3.5M | ||
| Q1 25 | $8.9M | $5.8M | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $9.3M | — | ||
| Q1 24 | $7.5M | — |
| Q4 25 | $-2.1M | $-17.0M | ||
| Q3 25 | $-883.8K | $-20.9M | ||
| Q2 25 | $-1.8M | $-22.7M | ||
| Q1 25 | $-1.2M | $-12.4M | ||
| Q4 24 | $-2.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-494.3K | — | ||
| Q1 24 | $-1.3M | — |
| Q4 25 | 35.3% | 11.3% | ||
| Q3 25 | 32.6% | 51.1% | ||
| Q2 25 | 36.4% | 73.7% | ||
| Q1 25 | 30.7% | 78.7% | ||
| Q4 24 | 32.2% | — | ||
| Q3 24 | 34.0% | — | ||
| Q2 24 | 25.3% | — | ||
| Q1 24 | 31.2% | — |
| Q4 25 | -20.9% | -387.7% | ||
| Q3 25 | -11.5% | -262.0% | ||
| Q2 25 | -21.8% | -652.3% | ||
| Q1 25 | -14.6% | -401.7% | ||
| Q4 24 | -21.7% | — | ||
| Q3 24 | -13.1% | — | ||
| Q2 24 | -13.6% | — | ||
| Q1 24 | -17.9% | — |
| Q4 25 | -25.0% | -373.5% | ||
| Q3 25 | -9.4% | -293.9% | ||
| Q2 25 | -18.8% | -642.2% | ||
| Q1 25 | -13.3% | -214.6% | ||
| Q4 24 | -22.5% | — | ||
| Q3 24 | -14.2% | — | ||
| Q2 24 | -5.3% | — | ||
| Q1 24 | -17.0% | — |
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-0.54 | $-0.06 | ||
| Q2 25 | $-0.82 | $-0.07 | ||
| Q1 25 | $-0.44 | $-0.04 | ||
| Q4 24 | $49.77 | — | ||
| Q3 24 | $-11.61 | — | ||
| Q2 24 | $-43.48 | — | ||
| Q1 24 | $-2.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $29.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.0M | $214.8M |
| Total Assets | $30.1M | $272.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $29.5M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $11.8M | ||
| Q1 25 | — | $56.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $23.0M | $214.8M | ||
| Q3 25 | $24.2M | $228.2M | ||
| Q2 25 | $25.7M | $249.2M | ||
| Q1 25 | $22.7M | $269.9M | ||
| Q4 24 | $23.5M | — | ||
| Q3 24 | $25.0M | — | ||
| Q2 24 | $23.5M | — | ||
| Q1 24 | $24.8M | — |
| Q4 25 | $30.1M | $272.6M | ||
| Q3 25 | $31.5M | $288.8M | ||
| Q2 25 | $32.0M | $290.5M | ||
| Q1 25 | $29.2M | $306.0M | ||
| Q4 24 | $30.6M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $29.3M | — | ||
| Q1 24 | $31.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-10.4M |
| Free Cash FlowOCF − Capex | $-1.6M | $-11.1M |
| FCF MarginFCF / Revenue | -18.9% | -243.7% |
| Capex IntensityCapex / Revenue | 0.0% | 15.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.5M | $-61.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | $-10.4M | ||
| Q3 25 | $-727.8K | $-14.3M | ||
| Q2 25 | $-1.3M | $-10.8M | ||
| Q1 25 | $-1.7M | $-22.8M | ||
| Q4 24 | $-3.4M | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | $-1.6M | $-11.1M | ||
| Q3 25 | $-735.8K | $-14.7M | ||
| Q2 25 | $-1.4M | $-11.6M | ||
| Q1 25 | $-1.7M | $-23.7M | ||
| Q4 24 | $-3.5M | — | ||
| Q3 24 | $-1.9M | — | ||
| Q2 24 | $-5.6M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | -18.9% | -243.7% | ||
| Q3 25 | -7.8% | -206.9% | ||
| Q2 25 | -15.2% | -329.6% | ||
| Q1 25 | -19.3% | -410.0% | ||
| Q4 24 | -36.6% | — | ||
| Q3 24 | -22.2% | — | ||
| Q2 24 | -59.7% | — | ||
| Q1 24 | -43.1% | — |
| Q4 25 | 0.0% | 15.6% | ||
| Q3 25 | 0.1% | 6.0% | ||
| Q2 25 | 1.7% | 22.8% | ||
| Q1 25 | 0.1% | 15.8% | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 0.8% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
